Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning

Response to androgen receptor signaling inhibitors (ARSI) varies widely in metastatic castration resistant prostate cancer (mCRPC). To improve treatment guidance, biomarkers are needed. We use whole-genomics (WGS; n = 155) with matching whole-transcriptomics (WTS; n = 113) from biopsies of ARSI-trea...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Anouk C., Danyi, Alexandra, van Riet, Job, de Wit, Ronald, Sjöström, Martin, Feng, Felix, de Ridder, Jeroen, Lolkema, Martijn P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082805/
https://www.ncbi.nlm.nih.gov/pubmed/37031196
http://dx.doi.org/10.1038/s41467-023-37647-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082805/
https://www.ncbi.nlm.nih.gov/pubmed/37031196
http://dx.doi.org/10.1038/s41467-023-37647-x

Ejemplares similares